Natalia is a partner in the Biotechnology group, advising leading life sciences companies on high-value therapeutics before the EPO, UPC and CJEU. With over 15 years’ experience in European patent practice,
including training and qualification at Carpmaels & Ransford, she is trusted by global innovators including Novartis, Biogen, Astellas, CSL, UCB and Neurocrine, as well as pioneering US East Coast biotechs at clinical and pre-clinical stages.
Clients value Natalia’s rigorous analysis and strategic thinking, as well as her ability to combine deep technical expertise with persuasive legal reasoning. She and her team develop and execute integrated, product-level IP strategies across gene therapies, nucleic acid-based therapies, antibodies, and engineered therapeutic proteins.
Natalia acts for clients in EPO oppositions and appeals and in UPC litigation, including technically and legally complex, commercially critical cases, both defending clients’ patents and challenging third-party rights to secure freedom-to-operate. This contentious focus informs a proactive and closely aligned approach to drafting, prosecution and SPC strategy, anticipating litigation risk and commercial realities to ensure robust, long-term protection.
